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Giien Shuen Chen4† and Shih-Hua Lin2,4*Abstract
Background: Hyponatremia is known to be a marker of poor prognosis in many clinical conditions. The association
between hyponatremia and clinical outcomes in peritoneal dialysis-related peritonitis (PDRP) has not been studied.
We evaluated the association between hyponatremia and clinical parameters of patients with PDRP.
Methods: We conducted a retrospective analysis of medical records of patients with PDRP admitted to a medical
center in the period 2004-2011. Patients with serum Na+ <130 mEq/L and ≥ 130 mEq/L at admission were divided
into hyponatremic and normonatremic groups, respectively. The demographic and laboratory characteristics,
pathogens of peritonitis, length of hospital stay and mortality rate were analyzed.
Results: Hyponatremia occurred in 27% (27/99) patients with PDRP. Gram-negative bacilli were the major pathogen
responsible for 78% (21/27) PDRP in hyponatremic group while gram-positive cocci were found in 75% (41/55)
PDRP in normonatremic groups. There was no significant difference in age, duration of dialysis, PD catheter removal
rate and technique failure between two groups. Hyponatremic group had significantly higher serum CRP (p <0.001),
lower serum albumin (p < 0.001) and phosphate (p < 0.05). Of note, serum Na+ level was positively correlated with
serum albumin (p < 0.001), phosphate (p < 0.04) levels, and subjective global assessment (SGA) score (p < 0.001).
Moreover, the length of hospital stay was longer and in-hospital mortality rate was higher in hyponatremic group
(p < 0.001). Using a multivariable logistic regression, we showed that hyponatremia at admission is an independent
predictor of in-hospital mortality (OR 76.89 95% CI 3.39-1741.67, p < 0.05) and long hospital stay (OR 5.37, 95%
CI 1.58- 18.19, p < 0.05).
Conclusions: In uremic patients with PDRP, hyponatremia at admission associated with a high frequency of gram
negative bacilli infection, low serum albumin and phosphate levels, low SGA score, and poor prognosis with long
hospital stay and high mortality rate.
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Hyponatremia is the most common electrolyte abnormal-
ities in clinical medicine [1]. The estimated prevalence of
hospitalized patients with serum sodium (Na+) less than
135 mEq/L was 15% [2,3]. Based on the underlying
mechanisms, hyponatremia could stem from a surplus
of electrolyte-free water (EFW) or a deficit of Na+ and/* Correspondence: l521116@gmail.com
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unless otherwise stated.or K+. The former mechanism is rarely caused by large
amount of water ingestion but the effect of ADH, which
impairs free-water clearance and results in water reten-
tion [4]. Inappropriate secretion of anti-diuretic hor-
mone (ADH) related to a variety of underlying diseases
or drugs is the most common cause of euvolemic hypo-
natremia in patients with normal renal function. Pa-
tients with acute or chronic kidney failure are more
susceptible to hypervolemic hyponatremia due to de-
creased renal water excretion. It has been constantly
reported that hyponatremia has a significant impact on
morbidity and mortality in various morbidities and alsotd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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peritoneal dialysis (PD) [5-7].
Continuous ambulatory peritoneal dialysis (CAPD)
has been used as a popular renal replacement therapy
for providing more flexibility of dialysis schedule and
preserving residual kidney function. Peritoneal dialysis-
related peritonitis (PDRP), the major complication of
CAPD, is the leading cause of severe morbidity, technique
failure and mortality in PD patients [8,9]. Although hypo-
natremia is not uncommon in PD patients with reported
incidence up to 14.5% [10], it is still unknown whether
hyponatremia associates with the clinical consequences of
PDRP. Here, we investigated the impact of hyponatremia
on clinical parameters and outcomes in hospitalized
patients with PDRP. Results to be reported indicate that
hyponatremia in patients with PDRP positively correlated
with the severity of underlying peritonitis, length of
hospital stay and in-hospital mortality.Methods
Patients
The study protocol was approved by the Ethics Com-
mittee on Human Studies at Tri-Service General Hospital,
National Defense Medical Center, in Taiwan, R.O.C. All
patients provided written informed consent prior to
participation. We retrospectively reviewed the medical
records of unselected PD patients who admitted to a
single medical center (Tri-Service General Hospital) due
to PDRP from January 2004 to December 2011. These pa-
tients received CAPD with standard glucose solution for
more than 3 months and were followed up monthly at
CAPD clinic. All patients were on disconnect system and
used 1.5 or 2 L bags of Baxter dialysate containing 1.5%,
2.5% or 4.25% glucose, which were exchanged 3-5 times
per day. Dialysate sodium concentration is 132 mmol/L. A
diagnosis of PDRP was made if the patient had at least
two of the following criteria: (A) clinical features of peri-
tonitis such as abdominal pain or cloudy peritoneal dialy-
sis effluent, (B) total leukocyte count ≧ 100 cells/mm3,
with more than 50% polymorphonuclear cells in the differ-
ential count, (C) positive gram stain or culture of periton-
eal dialysis effluent. All patients with PDRP were treated
with empiric antibiotics administered by the intraperito-
neal route. All patients did not have hemodialysis while
they underwent serum Na determination. We excluded
patients who had chronic hyponatermia or hyponatremia
before the event of PDRP, patients with pseudohypona-
tremia due to extracellular hyperosmolality secondary
to hyperglycemia, hyperlipidemia or the use of icodextrin-
based peritoneal dialysis or mannitol, and patients with-
out enough clinical parameters for analysis. In addition,
patients with other cormobid diseases, including hypothy-
roidism, adrenal insufficiency, liver cirrhosis and nephroticsyndrome, which might have impact on serum Na during
hospitalization, were also excluded.
Data collection
The following data were retrieved from the medical re-
cords of all eligible subjects: age, gender, primary renal
disease, residual renal function, peritoneal membrane
characteristics, dialysis adequacy, nutrition status, co-
morbidity and medication. The residual renal function
was measured using mean urea and creatinine clear-
ance. The membrane transport status was evaluated by
standard peritoneal equilibration test (PET) a month
after initiation of CAPD and then repeated every 6 month
as suggested [11]. Dialysis adequacy evaluated by dialysate
volume and averaged glucose concentration and small-
solute clearance determined by total Kt/V urea (the
sum of peritoneal Kt/V and renal Kt/V) prior to peri-
tonitis were recorded. We collected the laboratory data
on admission, including C-reactive protein (CRP), Na+,
K+, Cl-, creatinine, urea, total cholesterol, triglyceride,
total calcium, inorganic phosphate, albumin, total pro-
tein and fasting glucose measured by standard laboratory
techniques with automatic analyzer (AU 5000 chemistry
analyzer; Olympus, Tokyo, Japan). The nutrition status
measured as normalized protein nitrogen appearance
and 7-point subjective global assessment (SGA) score
was also recorded [12]. Co-morbidities, including con-
gestive heart failure, hypertension, diabetes mellitus, liver
cirrhosis, malignancy, systemic lupus erythematosus, were
obtained from previous history. Anti-hypertensive agents
including calcium channel blocker, α-adrenergic blocker,
β-adrenergic blocker, angiotensin-converting enzyme in-
hibitor, angiotensin-II blocker, thiazide, spironolactone
and furosemide were recorded. Microorganisms respon-
sible for each PDRP were collected. Clinical outcomes
of PDRP, including length of hospital stay, subsequent
peritonitis, removal of PD catheter, failure of peritoneal
dialysis and hospital mortality were evaluated.
Definition of hyponatremia
Hyponatremia was defined as serum Na+ concentra-
tion <130 mEq/L for 2 consecutive measures on the first
two days of admission. The patients were then divided
into hyponatremic group with serum Na+ <130 mEq/L
and normonatremic group with serum Na+ ≧130 mEq/L.
To accurately analyze the association between serum Na+
and serum albumin and phosphate, the effect of hypergly-
cemia on serum Na+ concentration was adjusted by the
formula as previously described [13].
Spectrum of microorganisms
All microorganisms responsible to PDRP were recorded.
To determine the influence of microbial spectrum on
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excluded.
Clinical outcomes
The clinical events and consequences including hospital
mortality, length of hospital stay, removal of PD catheter,
peritonitis episodes, and technique failure, were examined.
Hospital mortality was defined as any death occurred dur-
ing the same hospitalization or within one week after dis-
charge. Length of hospital stay in the patients who died
during hospitalization was calculated as the period from
the date of admission to that of death. Peritonitis episodes
were defined as any occurrence of recurrent, relapsed, and
repeated peritonitis. Technique failure was defined as any
failure of continued peritoneal dialysis after PDRP. To
understand if hyponatremia is an independent predictor
of outcomes in PDRP patients, we adjusted the effects of
multiple confounders of outcome of interest including
age, gender, spectrum of microorganisms and comorbidi-
ties, which was quantitatively scored by the Deyo modifi-
cation of Charlson comorbidity index (Deyo-CCI) [14-16].Table 1 Clinical characteristics on admission of patients with
Hyponatremic group
Gender (M/F) 10/17
Age (years) 49.1 ± 9.9





Systemic lupus erythematosus 3
Polycystic kidney disease 0
Unknown 3
Medication
Oral Hypoglycemic agent 1
α-adrenergic blocker 6
β-adrenergic blocker 6
Calcium channel blocker 15
ACEI or ARB+ 5
Furosemide 2
Na+ supplement 0
Number of 4.25% Dialysate (bags/day) 1.2 ± 0.8
Duration before antibiotics delivery (day) 1.1 ± 0.5
Co-morbidity: Deyo-CCI++ 3.6 ± 1.2
Subjective global assessment score 4.6 ± 1.2
Nutritional status: mean nPNA* 1.1 ± 0.3
RRF** (mL/min/1.73 m2) 1.2 ± 1.4
+ACEI or ARB, Angiorensin-convering enzyme inhibitor or Angiotensin-II receptor bl
the 6-month average of normalized protein nitrogen appearance, **RRF, residual reStatistical analyses
Data are expressed as mean ± standard deviations for con-
tinuous variables, and percentages for categorical vari-
ables. Chi-square test was used for categorical variables
and Pearson correlation coefficients for linear correlation.
All of the covariates were examined in univariate analyses.
Logistic regression analysis was performed to estimate the
risk of increased length of hospital stay, peritonitis epi-
sodes, Technique failure, removal of PD catheter and hos-
pital mortality. All statistical analyses were performed
using SPSS for window software version 18.0 (SPSS Inc.,
Chicago, IL, USA). For all analyses, statistical significance
was reached when a two-tailed p-value was less than 0.05.
Results
Patients’ characteristics
After excluding ineligible records, a total of 99 uremic pa-
tients with PDRP were enrolled for analysis. Twenty seven
(27%) patients had their serum sodium <130 mEq/L in
their hospital event of PDRP and were classified into
hyponatremic group. The demographic characteristics arePDRP
(n = 27) Normonatremic group (n = 72) p-value
48/24 0.015
52.6 ± 11.7 0.173














1.0 ± 0.7 0.144
1.1 ± 0.8 0.148
3.7 ± 1.5 0.755
5.7 ± 0.6 <0.001
1.2 ± 0.4 0.278
1.5 ± 1.5 0.257
ocker, ++Deyo-CCI, Deyo-charlson comorbidity index, *mean nPNA (mg/kg/day),
nal function.
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supplement before admission. While male was the
majority (66%, 48/72) in normonatremic group, female
was predominant (63%, 17/27) in hyponatremic group.
PDRP patients who developed hyponatremia did not
differ significantly in age, underlying renal diseases, nu-
tritional condition, prescribed medication, duration of
dialysis, osmolality of dialysate, duration between PDRP
onset and antibiotics treatment, the burden of comorbid
diseases included congestive heart failure (Deyo-CCI
score: 3.6 ± 1.2 vs. 3.7 ± 1.5), and residual renal function
(1.2 ± 1.4 vs. 1.5 ± 1.5 mL/min/1.73 m2) from those who
did not.
Laboratory studies and hyponatremia
As shown in Table 2, hyponatremic PDRP patients had
a significantly higher serum CRP (10.9 ± 2.9 vs. 4.5 ±
1.6 mg/dL, p <0.001), lower serum albumin (2.6 ± 0.7 vs.
3.3 ± 0.5 gm/dL, p < 0.001) and lower serum phosphate
(3.9 ± 1.3 vs. 5.3 ± 2.8 mg/dL, p < 0.05). The hyponatre-
mic group tended to have lower normalized protein ni-
trogen appearance (nPNA), a nutritional index of PD
patients (1.1 ± 0.2 vs. 1.2 ± 0.2 mg/kg/day), and SGA
score (4.6 ± 1.2 vs. 5.7 ± 0.6, p < 0.001). Using multi-linear
regression analysis, the serum sodium level was posi-






Na+ (mmol/l) 126.8 ± 2.4* 135 ± 3.4
K+ (mmol/l) 3.3 ± 0.7 3.7 ± 0.8
Cl- (mmol/l) 91.0 ± 2.6* 98.1 ± 4.2
Total calcium (mg/dl) 9.0 ± 1.0 9.0 ± 0.9
Phosphate (mg/dl) 3.9 ± 1.3* 5.3 ± 2.8
C-reactive protein
(mg/dl)
10.9 ± 2.9** 4.5 ± 1.6
Albumin (mg/dl) 2.6 ± 0.7** 3.3 ± 0.5
Triglyceride (mg/dl) 163.9 ± 19.6 164.0 ± 24.0
Cholesterol (mg/dl) 191.3 ± 34.4 197.8 ± 20.4
Blood urea nitrogen
(mg/dl)
64.3 ± 22.7 64.3 ± 21.0
Uric acid (mg/dl) 5.6 ± 1.5 6.1 ± 1.5
Glucose (mg/dl) 109.9 ± 18.5 119.7 ± 32.4
Membrane transport
(U/P Cr)
0.7 0 ± 0.1 0.64 ± 0.1
WCC+ (L/week/
1.73 m2)
62.6 ± 10.3 68.9 ± 16.7
nPNA++ (mg/kg/day) 1.1 ± 0.3 1.2 ± 0.4
Weekly Kt/V 1.9 ± 0.4 2.1 ± 0.4
*p value < 0.05, **p value < 0.001, +WCC, weekly creatinine clearance, ++nPNA,
normalized protein nitrogen appearance.P < 0.001), serum phosphate level (r = 0.205, p < 0.04), and
SGA score (r = 0.352, p < 0.001). There were no significant
difference in small solute clearance/U/P Cr (0.70 ± 0.1 vs.
0.64 ± 0.1), WCC (62.6 ± 10.3 vs. 68.9 ± 16.7 L/week/
1.73 m2) and weekly Kt/V (1.9 ± 0.4 vs. 2.1 ± 0.4) and other
laboratory studies between two groups.
Spectrum of microorganisms and hyponatremia
Gram-positive cocci (GPC), gram-negative bacilli (GNB)
and fungus accounted for 47, 35 and 2 episodes of
all PDRP, respectively. The remaining 15 episodes were
culture-negative. Among patients with gram-negative peri-
tonitis, Pseudomonas aeruginosa was the leading pathogen
(28.6%, 10/35), followed by Escherichia coli (22.9%, 8/35),
Enterobacter species (20%, 7/35), Klebsiella pneumoniae
(11.4%, 4/35), Acinetobacter species (5.7%, 2/35), and the
others (11.4%, 4/35). Nine of patients with gram-negative
peritonitis had prodromal diarrhea at presentation. In
regard to gram-positive peritonitis, the most common
isolated pathogen was Staphylococcus aureus (48.9%,
23/47), followed by Staphylococcus epidermidis (29.8%,
14/47), Streptococcus species (12.8%, 6/47), Enterococcus
species (6.4%, 3/47), and others (2.1%, 1/47). We com-
pared the microbial spectrum of PDRP between two
groups and showed that hyponatremic PDRP patients
had higher incidence of gram-negative peritonitis (21/
27, 77.8% versus 6/27, 22.2%, p <0.001), while normona-
tremic PDRP patients were more likely to have gram
positive peritonitis (41/55, 74.5% versus 14/55, 25.5%,
p < 0.05). The association analysis of microbial spectrum
and clinical outcomes showed that patients with gram-
negative PDRP had a significantly higher hospital mor-
tality (6/35 versus 2/45, p = 0.022) and longer length of
hospital stay (11.0 ± 4.0 versus 8.4 ± 3.2 days, p = 0.001)
(Table 3). Pseudomonas aeruginosa was known to be
highly virulent and caused higher hospital mortality rate
than other pathogens (4/10, 40% versus 4/72, 5.7%). Of
note, patients in this subgroup of Pseudomonas aerugi-
nosa-induced PDRP had higher incidence of hypona-
tremia than those with non-Pseudomonas aeruginosa
gram-negative PDRP (7/10, 70.0% versus 14/25, 56.0%).
Clinical outcomes and hyponatremia
The overall hospital mortality rate of patients with PDRP
was 8.1% (8/99). Hyponatremic PDRP patients had a sig-
nificantly higher hospital mortality rate (25.9% vs. 1.4%,
p < 0.001) than normonatremic group, even after correc-
tion of hyponatremia. Hyponatremic group also had lon-
ger lengths of hospital stay (11.9 ± 4.3 vs. 8.3 ± 2.9 days,
p < 0.001) than normonatremic group (Table 4). There
were no significant differences in the incidences of other
hospital events, including removal of PD catheter, tech-
nique failure, and peritonitis episodes between two groups.
Using univariate analysis, we identified that hyponatremia
Table 3 The relationship between spectrum of microorganisms and clinical outcomes
Length of stay Technique failure Removal of PD catheter Peritonitis episodes Hospital mortality
GPC++ (47) 8.4 ± 3.2* 5 6 12 2**
GNB+ (35) 11.0 ± 4.0* 9 6 9 6**
Non-P.A. (25) 9.1 ± 3.6*** 7 4 7 2***
P. A.+++ (10) 11.3 ± 4.3*** 2 2 2 4***
+GNB, gram-negative bacilli, ++GPC, gram-positive cocci, +++P.A., Pseudomonas aeruginosa, *p =0.001, **p = 0.022, ***p = 0.071, ***p = 0.003.
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hospital mortality (OR 24.85 95% CI 2.89-214.02, p =
0.003; OR 14.17 95% CI 2.82-71.18, p = 0.001), and hypo-
natremia and female gender linked to longer length of
hospital stay (OR 7.75 95% CI 2.82-21.30, p <0.001; OR
2.77 95% CI 1.10-7.03, p = 0.032) (Table 5). To eliminate
the potential effects of other covariates of clinical out-
comes, multivariable logistic regression were applied to
adjust age, gender, Deyo-CCI score, gram negative bacilli
and Pseudomonas aeruginosa infection, and serum Na+
concentration. Hyponatremia remained independently as-
sociated with increased hospital mortality (OR 76.89 95%
CI 3.39-1741.67, p = 0.006) and increased length of hos-
pital stay (OR 5.37, 95%CI 1.58- 18.19, p =0.007). How-
ever, hyponatremia did not affect the occurrence of
technique failure, removal of PD catheter, and peritonitis
recurrence (Figure 1).
Discussion
The current study represented the first to demonstrate the
prognostic significance of hyponatremia in uremic patients
with PDRP. Hyponatremia exerted a negative influence on
length of hospital stay and in-hospital mortality independ-
ently, even after the adjustment for age, gender, spectrum
of pathogens and co-morbidity. Our results suggested that
hyponatremia per se is a surrogate marker of poor clinical
outcome in uremic patients with PDRP.
The cutoff value of serum Na+ 130 mEq/L has been
popularly used to define hyponatremia in many studies
[17-19]. In this study, the incidence of hyponatremia in
PDRP patients was approximately 27%, much higher








11.9 ± 4.3* 8.3 ± 2.9
Technique failure 5/27 (18.5%) 9/72 (12.5%)
Removal of PD++
catheter
3/27 (11.1%) 9/72 (12.5%)
Peritonitis episodes 6/27 (22.2%) 22/72(30.6%)
Hospital mortality 7/27 (25.9%)* 1/72 (1.4%)
+Peritoneal dialysis-related peritonitis, ++PD, peritoneal dialysis, *p value < 0.001.with community-acquired pneumonia [18,19]. The re-
ported incidences of hyponatremia in PD population
varied greatly from 2.4% to 14.5% [10,17]. It seems likely
that PDRP patients are more susceptible to hyponatremia
than general PD patients. People have proposed several
mechanisms to explain the development of hyponatremia
in PD, including [1] net water gain due to excessive water
intake or low ultrafiltration rate of free-water [2], negative
Na+/K+ balance caused by low Na+/K+ intake or high
Na+/K+ removal, and [3] shift of intracellular water to
extracellular space induced by the use of icodextrin or
hypercatabolism and malnutrition [17,20]. It is still un-
known why PDRP patients have higher incidence of
hyponatremia than other PD patients. Our speculation
is that peritonitis may disrupt aquaporin-mediated water
removal, reduce Na+ intake due to poor appetite, and,
probably most important, lead to a hypercatabolic state, in
which intracellular osmoles, such as protein, nucleic acids,
phosphates, are degraded and thus move intracellular
water into extracellular space. Compatible with this con-
cept, we showed that the Na+ concentration in PDRP was
positively correlated with serum albumin and phosphate
levels, and SGA, indicating the relationship between
serum Na+ and nutritional status in PDRP patients.
By analyzing the microbial spectrum of PDRP, we found
that patients with hyponatremia had higher percentage of
gram-negative peritonitis than those without hyponatre-
mia. It is known that gram-negative microorganisms enter
peritoneum mainly through direct transmural migra-
tion from gut [21]. The underlying pathogenesis of this
phenomenon is still unclear. It is possible that the hy-
poalbuminemia and malnutrition (lower nPNA) cause
swelling of the intestinal mucosa and loss of intestinal
barrier integrity, and thus allow the normal gut flora
penetrate into peritoneum [22]. Furthermore, our results
demonstrated that gram-negative peritonitis, especially
Pseudomonas aeruginosa, had poorer clinical outcome
than those with gram-positive peritonitis, compatible with
previous findings [23-25]. Gram-negative microorganisms
have adapted to many antibiotics, especially the first-line
β-lactams antibiotic treatment, and may therefore exagger-
ate the severity of peritonitis [26]. Similarly, Szeto et al.
reviewed the gram-negative PDRP and suggested that
Pseudomonas species were the most important cause of
serious peritonitis in PD patients [27]. Although higher
Table 5 Logistic regression analysis of risk factors of hospital mortality and length of hospital stay
Hospital mortality Length of hospital stay+
Univariate Multivariate Univariate Multivariate
OR 95% CI p value OR 95% CI p value OR 95% CI p value OR 95% CI p value
Age 1.05 0.98,1.13 0.164 1.17 1.01, 1.37 0.038 0.97 0.95,1.03 0.485 1.01 0.95, 1.06 0.830
Gender++ 0.84 0.19,3.72 0.815 0.54 0.07, 4.33 0.562 2.77 1.10,7.03 0.032 1.93 0.62, 6.06 0.259
Deyo-CCI* 1.04 0.64,1.70 0.863 0.70 0.30, 1.62 0.401 1.01 0.74,1.38 0.957 1.07 0.71, 1.63 0.737
Na** 24.85 2.89,214.02 0.003 76.89 3.39, 1741.67 0.006 7.75 2.82,21.30 <0.001 5.37 1.58, 18.19 0.007
P. A.*** 14.17 2.82,71.18 0.001 5.92 0.57, 61.87 0.137 2.16 0.56,8.38 0.266 0.72 0.14, 3.74 0.698
+Length of hospital stay, median number of length of stay (12 days) of patients in group I was used for logistic regression analysis, ++Gender, female versus male,
*Deyo-CCI, Deyo-charlson comorbidity index, **Na, hyponatremia versus normal ***P.A., Pseudomonas aeruginosa.
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ported in patients with Pseudomonas aeruginosa periton-
itis, we did not observe this phenomenon, probably due to
small number of Pseudomonas aeruginosa peritonitis in
this study. Culture-negative peritonitis accounted for
15.2% of all PD peritonitis in the study, similar to most of
the reported series [28-30].
It seems plausible that the trend of gram-negative
microorganism infection per se can lead to overall poorer
clinical outcomes in PDRP patient with hyponatremia.
However, the fact that hyponatremia associates with poor
prognosis in various clinical situations implies the poten-
tial effect of hyponatremia on clinical course of PDRP. In-
deed, we confirmed that hyponatremia at admission was
independently associated with hospital length of stay and
hospital mortality rate in PDRP patients. The underlying
mechanisms of hyponatremia-induced poor clinical out-
comes are mostly unknown. Therefore, it is difficult to
confirm the direct causal relationship between hyponatre-
mia and outcomes of clinical diseases at present [31]. A
recent study performed microarray analysis in cells main-
tained in low sodium (90-127 mEq/L), and found that
genes involved in cell death and survival are mostly altered
[32]. These detrimental effects of hyponatremia areFigure 1 Adjusted risk for hospital mortality, length of hospital stay,
in patients with and without hyponatremia. 95% confidence intervals in
outcomes were derived from logistic regression models and adjusted for aindependent of osmolality and cause neural toxicity
in vitro. In humans, hyponatremia was usually mild and
may not generate the similar in vitro effects. Konstam et
al had demonstrated that correction of hyponatremia by
using vasopressin antagonist in patients with congestive
heart failure does not improve prognosis [33]. Further-
more, Kin et al. showed that the effect of hyponatremia
on mortality diminished as the severity of end-stage
liver disease increased [34]. These studies support the
notion that severe underlying disease worsens hypona-
tremia and clinical outcome and hyponatremia itself
may be a surrogate marker for the severity of underlying
disease [35]. Several studies have shown the association
between hyponatremia and severe inflammation in clin-
ical infectious diseases [36].
There were some limitations in this study. First, we
were unable to evaluate the effect of correction of serum
Na+ level on clinical outcome owing to the retrospective
fashion of analysis. Second, although there were crude
associations between hyponatremia and outcomes, we
acknowledged the possibility of existence of residual
confounders despite multivariable analysis. Third, this
study was limited to relatively small sample size in
PDRP patients with hyponatremia.technique failure, removal of PD catheter and peritonitis episodes
dicating the individual contribution of hyponatremia to the respective
ge, gender, Deyo-CCI score and the Pseudomonas aeruginosa infection.
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Hyponatremia on admission is common in uremic patients
with PDRP. It is independently associated with poor clinical
outcomes including increased length of hospital stay and
hospital mortality. The association of hyponatremia and
poor prognosis may be a reflection of initial severity of
illness. Patients with PDRP who developed hyponatremia
at admission may need more aggressive therapy and more
intensive monitoring during hospitalization.
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